Company Description
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors.
In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease.
Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A.
The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx.
Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
| Country | Denmark |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,678 |
| CEO | Jan G.J. de Winkel |
Contact Details
Address: Carl Jacobsens Vej 30, Valby Copenhagen, 2500 Denmark | |
| Phone | 45 70 20 27 28 |
| Website | genmab.com |
Stock Details
| Ticker Symbol | GMAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| CIK Code | 0001434265 |
| CUSIP Number | 372303206 |
| ISIN Number | US3723032062 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President and Chief Executive Officer |
| Anthony Pagano CPA | Executive Vice President and Chief Financial Officer |
| Birgitte Stephensen M.Sc. | Executive Vice President and Chief Legal Officer |
| Christopher Cozic | Executive Vice President and Chief People Officer |
| Dr. Martine J. van Vugt Ph.D. | Executive Vice President and Chief Strategy Officer |
| Martin Schultz | Senior Director of Clinical Operations and Non-Independent Director |
| Dr. Judith V. Klimovsky M.D. | Executive Vice President and Chief Development Officer |
| Dr. Tahamtan Ahmadi | Executive Vice President, Chief Medical Officer and Head of Experimental Medicines |
| Dr. Mijke Zachariasse Ph.D. | Senior Director, Head of Antibody Research Materials and Non-Independent Director |
| Takahiro Hamatani | Senior Director of Finance Japan and Non-Independent Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 13, 2025 | 6-K | Report of foreign issuer |
| Feb 12, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 12, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Feb 12, 2025 | 6-K | Report of foreign issuer |
| Jan 29, 2025 | 6-K | Report of foreign issuer |
| Jan 23, 2025 | 6-K | Report of foreign issuer |
| Jan 22, 2025 | 6-K | Report of foreign issuer |
| Dec 4, 2024 | 6-K | Report of foreign issuer |
| Dec 3, 2024 | 6-K | Report of foreign issuer |
| Dec 3, 2024 | 6-K | Report of foreign issuer |